Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose

NCT03943875 is registered in ClinicalTrials.gov with The University of Texas Medical Branch, Galveston as lead sponsor.

NCT NCT03943875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03943875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
GARDASIL 9: 3 Dose vs. 2 Dose With Delayed 3rd Dose
Lead sponsor
The University of Texas Medical Branch, Galveston
Phase
Phase 4
Overall status
Completed
Start date
June 17, 2019
Completion date
January 13, 2025
Enrollment
767 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

efficacy, human papilloma virus, immunization